Free Trial
NASDAQ:HURA

TuHURA Biosciences 5/15/2025 Earnings Report

TuHURA Biosciences logo
$2.70 -0.11 (-3.91%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$2.72 +0.02 (+0.74%)
As of 08/29/2025 07:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TuHURA Biosciences EPS Results

Actual EPS
-$0.15
Consensus EPS
-$0.13
Beat/Miss
Missed by -$0.02
One Year Ago EPS
N/A

TuHURA Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

TuHURA Biosciences Announcement Details

Quarter
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

TuHURA Biosciences' next earnings date is estimated for Monday, October 6, 2025, based on past reporting schedules.

Conference Call Resources

TuHURA Biosciences Earnings Headlines

TuHURA Biosciences (NASDAQ:HURA) Stock Rating Lowered by Wall Street Zen
Elon’s BIGGEST warning yet?
Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.tc pixel
See More TuHURA Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like TuHURA Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on TuHURA Biosciences and other key companies, straight to your email.

About TuHURA Biosciences

TuHURA Biosciences (NASDAQ:HURA) (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced or metastatic Merkel Cell Carcinoma. In addition to its innate immune response agonist candidates, TuHURA is leveraging its Delta receptor technology to develop first-in-class bi-specific ADCs, and PDCs targeting Myeloid Derived Suppressor Cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.

View TuHURA Biosciences Profile

More Earnings Resources from MarketBeat